关注并星标CPHI制药在线布鲁顿酪氨酸激酶（BTK）抑制剂的崛起，正在重塑血液肿瘤与自身免疫性疾病的治疗格局。2025年8月29日，美国 FDA 批准赛诺菲（Sanofi）的 Rilzabrutinib 用于治疗成人持续性或慢性免疫性血小板减少症（ITP），成为首个获批用于该适应症的 BTK 抑制剂；而此前礼来（Lilly）的Pirtobrutinib作为首个非共价 BTK 抑制剂获批，为对传统...
Source Link关注并星标CPHI制药在线布鲁顿酪氨酸激酶（BTK）抑制剂的崛起，正在重塑血液肿瘤与自身免疫性疾病的治疗格局。2025年8月29日，美国 FDA 批准赛诺菲（Sanofi）的 Rilzabrutinib 用于治疗成人持续性或慢性免疫性血小板减少症（ITP），成为首个获批用于该适应症的 BTK 抑制剂；而此前礼来（Lilly）的Pirtobrutinib作为首个非共价 BTK 抑制剂获批，为对传统...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.